Editas Medicine, Inc. (EDIT)
Uses CRISPR gene editing to develop one-time treatments for genetic diseases.
$2.58-0.04%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago+5.5%
The outlook
Editas Medicine is trading near the lower end of its 52-week range and below both its 50- and 200-day moving averages, signaling weak near-term momentum. Analysts' average price target sits about 124% above the current price, though overall sentiment leans bearish at 36/100.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range32% of the way from its 52-week low to high
Price targetAvg target +124% vs current price
Analyst price target
~12-month · 9 analysts$5.78average target+124.4% vs now
Now $2.58
Low $1.00High $15.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$395.2M
52-wk high
$4.54
52-wk low
$1.66
50-day avg
$2.92
200-day avg
$2.66
Trailing P/E
—